Recon: Eli Lilly to invest $27B in US drug manufacturing; India’s CDSCO to streamline export processes

• The Trump years will be grim for long Covid sufferers (STAT)
• New York congressman launches examination of UnitedHealth clinics in Hudson Valley (STAT)
• FDA cancels vaccine advisory committee meeting (STAT)
• Why NIH pays universities far more for indirect costs than private foundations (STAT)
• Eli Lilly announces $27 billion investment in U.S. drug manufacturing sites (STAT)
• Trump Administration Orders Bird Flu Shot Review (Bloomberg)
• Medicare spending on common diabetes drugs skyrocketed, HHS inspector general finds (Endpoints)
• Despite WHO exit plan, US still in Americas health agency (Reuters)
• With RFK Jr. in Charge, Supplement Makers See Chance to Cash In (Medpage Today)

• Services collapsing as USAID cuts health contracts worldwide (Reuters)
• Q&A: How Trump’s USAID freeze halted the effort to develop an effective HIV vaccine in Africa (STAT)
• Mpox Strain With Higher Transmission Rate Circulating in Congo (Bloomberg)
• Healthcare experts urge India to rewrite clinical trial rules to boost global market share (Reuters)
• India's drug regulator to streamline export process to reduce workload (Reuters)
• India's contract drug makers seek government support in China fight (Reuters)

• New kids on the block: A new generation of VCs ventures into biotech (STAT)
• How to eliminate biotech zombies: Buy them (STAT)
• Novavax's quarterly loss shrinks as it ramps down spending on COVID vaccines (Reuters)
• Can Bill Anderson save Bayer? (Endpoints)
• Hansoh ends collaboration with Silence; Vir hunts for HBV drug partner (Endpoints)
• Merck mulls new site in Delaware; Granules India buys peptide CDMO (Endpoints)
• Kallyope quietly reports Phase 2 obesity data, begins mid-stage migraine trial (Endpoints)
• Startup working on oral antibodies shares early ulcerative colitis data (Endpoints)
• After rejection, Regeneron seeks accelerated approval of bispecific for only one of two types of lymphoma (Endpoints)
• AstraZeneca’s SERD hits primary endpoint in late-stage trial, but first-line potential remains uncertain (Endpoints)
• ‘Fear and uncertainty’: Biotech investors warn of impact from NIH research cuts (MedTech Dive)

• Teladoc reports $1B net loss as it works to turn around its business (Endpoints)
• Staar Surgical to lay off 115 people in California (MedTech Dive)
• CAP urges HHS to revoke lab developed test rule, citing Trump order (MedTech Dive)
• EU Law First Up As UK MHRA Reopens Work On Pre-Market Medtech Regulation (MedTech Insight)
• Seonix Bio’s Newly Launched Saliva-Based Genetic Test Aims To Shed Light On Glaucoma Risk Assessmentb (MedTech Insight)
• Government Cuts ‘Penny-Wise, Pound-Foolish,’ Rare Disease Advocates Fret (MedTech Insight)

• CDC will no longer process transgender data (STAT)
• There’s a better way to get drugs on the market: progressive approval (STAT)
• Medicare Advantage enrollment growth slows drastically (STAT)
• Texas measles outbreak marks first fatality as more cases reported (STAT)
• Trump administration takes aim at bird flu. For now, the cattle will have to wait (STAT)
• How ultra-processed foods captured the baby and toddler market (STAT)
• RFK Jr.’s dangerous misuse of ‘informed consent’ on vaccines (STAT)